Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.44 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | CA9 | Q16790 | 3/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA3 | P07451 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA6 | P23280 | 1/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21190844 | 0.89 | BRD4 (0.44) | BRD4CA1CA2CA9CA12 | |
| SCHEMBL21190847 | 0.88 | BRD4 (0.42) | BRD4CA1CA2CA9CA12 | |
| SCHEMBL20155574 | 0.79 | ALDH1A1 (0.41) | CA1CA2CA9CA12CA3 | |
| SCHEMBL21190843 | 0.79 | BRD4 (0.45) | BRD4CA1CA2CA9PTGS2 | |
| SCHEMBL21191131 | 0.78 | MET (0.36) | BRD4CA1CA2CA9PTGS1 | |
| SCHEMBL2522891 | 0.76 | LPL (0.36) | CA1CA2CA9CA12CA3 | |
| SCHEMBL20157282 | 0.76 | LIPG (0.37) | BRD4CA1CA2CA9CA12 | |
| SCHEMBL17492736 | 0.75 | BRD4 (0.50) | BRD4P2RX3CA1CA2CA9 | |
| SCHEMBL21190846 | 0.75 | LPL (0.36) | BRD4CA1CA2CA9CA12 | |
| SCHEMBL17492543 | 0.72 | P2RX3 (0.52) | BRD4P2RX3CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200354371-A1 | BROMODOMAIN INHIBITOR COMPOUND AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-11-12 | — | — | US | disclosed |
| WO-2019141131-A1 | BROMODOMAIN INHIBITOR COMPOUND AND USE THEREOF | 中国科学院上海药物研究所 | 2019-07-25 | — | — | WO | disclosed |
| US-9359548-B2 | Organic electroluminescent device | UDC IRELAND LIMITED (IE) | 2016-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200354371-A1 | BROMODOMAIN INHIBITOR COMPOUND AND USE THEREOF | BRD4, BRD1, BRD3 | BRD4 1/4885P2RX3 4394/4885CA1 2663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.